Peptides for Eye Health: Epithalon, Retinalamin, Carnosine Eye Drops, and Vision Research

Age-related vision decline is among the most feared consequences of aging, yet ophthalmology has historically had limited regenerative tools. Peptide research, particularly from Russian bioregulator science, has produced several compounds with meaningful evidence for retinal protection, lens clarity, and optic nerve support.

This guide covers the most researched peptides for eye health, from established bioregulators used clinically in Eastern Europe to emerging research compounds.

The Biology of Age-Related Vision Decline

Several mechanisms drive vision loss with age:

• Oxidative stress in the lens: Accumulation of oxidized proteins (particularly crystallins) causes lens clouding — cataracts
• Retinal pigment epithelium (RPE) dysfunction: The RPE supports photoreceptors; its decline is central to age-related macular degeneration (AMD)
• Mitochondrial failure in photoreceptors: Rods and cones are extraordinarily metabolically demanding; mitochondrial dysfunction accelerates photoreceptor death
• Reduced neurotrophic support: Declining BDNF and NGF levels reduce optic nerve and retinal ganglion cell survival
• Vascular compromise: The retina depends on precise microvascular supply; diabetic retinopathy and AMD both involve vascular pathology

Effective peptides for eye health must address one or more of these pathways.

Epithalon: Pineal-Derived Longevity Peptide

Epithalon (Epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by the St. Petersburg Institute of Bioregulation and Gerontology. It is the synthetic analog of epithalamin, derived from the pineal gland.

Eye-Specific Research

Epithalon's ophthalmic effects were discovered in research on aging rats. Key findings:

• Retinal structure preservation: Aged rats treated with Epithalon showed significantly better preservation of photoreceptor cells (rods and cones) compared to untreated controls
• Reduced retinal oxidative damage: Epithalon reduces lipid peroxidation in retinal tissue, protecting against oxidative degeneration
• Improved electroretinogram response: Functional retinal activity (measured by ERG) was maintained at higher levels in treated animals through advanced age
• Melatonin normalization: Epithalon restores pineal melatonin secretion, and melatonin itself is a potent retinal antioxidant with direct photoreceptor protective effects

One of the landmark studies by Khavinson et al. followed elderly individuals receiving Epithalon courses over several years and found preserved visual acuity compared to age-matched controls.

Protocol: 5–10 mg subcutaneous or IV injection daily for 10-day courses, repeated 1–2 times per year. Intranasal use is also common. See the Epithalon peptide guide for full longevity protocols.

Retinalamin: The Retinal-Specific Bioregulator

Retinalamin is a polypeptide bioregulator extract derived from bovine retinal tissue. It is one of the most specific eye-health peptides available, designed to deliver tissue-specific bioregulatory signals directly to retinal cells.

Mechanism and Evidence

Retinalamin works through the bioregulator principle: peptide fragments from retinal tissue normalize gene expression in equivalent human retinal cells. Proposed mechanisms include:

• RPE regeneration support: Retinalamin promotes proliferation and functional normalization of retinal pigment epithelium cells — the support layer critical for photoreceptor survival
• Photoreceptor neuroprotection: Reduces apoptosis in photoreceptor cells under oxidative stress
• Anti-glaucomatous effects: Clinical research from Russia reports reduced intraocular pressure and improved visual field stability in glaucoma patients treated with Retinalamin
• Retinitis pigmentosa support: Several Russian clinical studies describe slowed progression of retinitis pigmentosa with Retinalamin injections

A controlled clinical study (Shamshinova et al.) in 30 patients with retinitis pigmentosa found that Retinalamin parabulbar injections improved electroretinogram amplitude and visual acuity in the treatment group, with no significant changes in controls.

Protocol: 5 mg parabulbar (near-eye) injection daily for 10 days, repeated every 3–6 months. Parabulbar administration requires clinical training. Some practitioners use systemic (IM) injection as an alternative.

N-Acetylcarnosine Eye Drops: Cataract Research

N-acetylcarnosine (NAC, distinct from N-acetylcysteine) is a dipeptide prodrug that penetrates the cornea and lens, where it is converted to carnosine. Carnosine is a powerful antioxidant and anti-glycation agent.

Cataract Mechanism and Evidence

Cataracts form when crystallin proteins in the lens become cross-linked and aggregated due to oxidation and glycation. Carnosine counteracts both processes:

• Antioxidant protection: Carnosine scavenges reactive oxygen species that oxidize crystallin proteins
• Anti-glycation: Carnosine competes with glucose in glycation reactions, reducing lens protein cross-linking
• Protein disaggregation: Some research suggests carnosine can actually dissolve early protein aggregates in the lens

The landmark clinical study by Babizhayev et al. (2002) evaluated 1% NAC eye drops in 49 patients with cataracts over 24 months. Eyes treated with NAC showed improvement in lens transparency in 90% of cases, versus no improvement or worsening in the placebo group. Visual acuity improved in 88.9% of treated eyes.

Subsequent studies have been smaller but generally supportive. NAC eye drops remain the most evidence-backed non-surgical intervention for early to moderate cataracts.

Protocol: 1–2 drops of 1% N-acetylcarnosine solution in each affected eye, twice daily. Commercial products (Can-C, Bright Eyes) are available without prescription. Improvement typically requires 3–6 months of consistent use.

Cortexin: Neuropeptide Support for the Optic Nerve

Cortexin is a polypeptide bioregulator derived from bovine cortical brain tissue. While primarily known for neurological applications (cognitive support, stroke recovery), its neuroprotective effects extend to the optic nerve.

Optic Nerve Applications

• Glaucomatous optic neuropathy: Cortexin has been studied in patients with primary open-angle glaucoma alongside conventional pressure-lowering therapy. Results suggest improved visual field indices and RNFL (retinal nerve fiber layer) preservation
• Optic neuritis recovery: Case series describe improved visual acuity recovery in optic neuritis with Cortexin treatment
• BDNF and NGF upregulation: Cortexin's neuroprotective effects are mediated in part through increased neurotrophic factor production — relevant for retinal ganglion cell survival, which depends on NGF and BDNF

Protocol: 10 mg IM injection daily for 10 days, repeated every 3–6 months.

BPC-157 and Eye Inflammation

BPC-157 is not a traditional "eye peptide," but its systemic anti-inflammatory and vascular effects are relevant to inflammatory eye conditions:

• Uveitis: BPC-157's modulation of NF-κB reduces intraocular inflammatory cascades
• Post-surgical healing: Corneal and conjunctival wound healing may benefit from BPC-157's tissue repair mechanisms
• Dry eye: Preliminary evidence suggests BPC-157 supports mucosal membrane integrity, potentially relevant to ocular surface disease

See the BPC-157 peptide guide and the peptides for inflammation guide for more.

Combining Eye Health Peptides

A comprehensive eye health protocol for prevention and early AMD or cataract:

| Goal | Peptide | Route | Frequency | |------|---------|-------|-----------| | Retinal preservation | Epithalon 10 mg | SubQ or IV | 10-day course, 2x/year | | Lens protection | NAC eye drops 1% | Topical drops | Twice daily, continuous | | Optic nerve support | Cortexin 10 mg | IM | 10-day course, 2x/year | | Active retinal degeneration | Retinalamin 5 mg | Parabulbar | 10-day course, 2-4x/year |

Other Research Compounds

Crystallin peptide fragments: Synthetic fragments of alpha-crystallin (particularly αB-crystallin 73-92) have demonstrated retinal protection in animal models of AMD and diabetic retinopathy. These are research-stage but promising.

VEGF-inhibitor peptides: The gold standard treatment for wet AMD is anti-VEGF therapy (ranibizumab, bevacizumab). Research into smaller peptide-based VEGF inhibitors that could be taken systemically or orally is ongoing.

SS-31 (Elamipretide): A mitochondria-targeting peptide that is in Phase II clinical trials for geographic atrophy (late dry AMD). Its ability to restore photoreceptor mitochondrial function makes it mechanistically compelling. See the SS-31 peptide guide.

Frequently Asked Questions

Q: Can N-acetylcarnosine eye drops actually reverse cataracts? The evidence suggests they can improve transparency in early to moderate cataracts. Mature cataracts with significant structural changes are unlikely to respond. Results from clinical studies suggest improvement in visual acuity and lens clarity in the majority of treated patients with early/moderate disease. They should not be considered a replacement for surgical evaluation when cataracts significantly impair function.

Q: How is Retinalamin administered — can it be done at home? Parabulbar injection (injection into the space near but not inside the eye) requires clinical training and should not be attempted at home. Some practitioners offer intramuscular injection as an alternative with systemic tissue-specific effects, though parabulbar delivery provides higher local concentrations.

Q: Is Epithalon specifically effective for age-related macular degeneration? The research is most robust for general retinal aging and retinitis pigmentosa. AMD-specific data is limited, but Epithalon's retinal oxidative protection and RPE support mechanisms are directly relevant to dry AMD pathology.

Q: Can any of these peptides help with glaucoma? Retinalamin and Cortexin have the most direct evidence for glaucoma. Both have shown visual field improvement and neuroprotective effects in open-angle glaucoma studies. They do not lower intraocular pressure but protect the optic nerve from pressure-induced damage.

Q: Are carnosine eye drops the same as N-acetylcarnosine eye drops? No. Standard carnosine does not penetrate the cornea effectively. N-acetylcarnosine is the esterified prodrug form that penetrates ocular tissues and is then hydrolyzed to active carnosine within the lens. Use only N-acetylcarnosine formulations for cataract applications.